Clinical trials: Central Nervous System Tumors
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03803761
- Testing
- Copanlisib, Fulvestrant
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts
Acute Lymphoblastic Leukemia
Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
The purpose of this study is to describe the activity and toxicity of a new formulation of cytarabine called liposomal cytarabine given into the central nervous system for the treatment of central nervous system localization of…
- Trial name
- CILI (NCT01593488)
- Testing
- liposomal cytarabine
- Where
- 10 sites in Italy
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute, Naples
Pediatric ALL, Spinal Cord Injuries
Spinal Cord Injury in the Pediatric Population - an International Multicenter Study
INTRODUCTION: Due to the low incidence of pediatric spinal cord injury (SCI) and the high demand for knowledge and research, international cooperation is needed to build a solid and shared understanding of the extent of the…
- Trial name
- SINpedSCI (NCT04117854)
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 30 people
- Sponsor
- Sunnaas Rehabilitation Hospital
Primary Brain Tumor, Neurocognition
Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life
Significant advances in primary malignant brain tumors (PBT) treatment have led to dramatically improved survival, both in children and adults.
- Conditions
- Primary Brain Tumor, Neurocognition, Quality of Life
- Trial name
- NEUROCOG-QOL (NCT02693405)
- Testing
- Executive functions, social cognition, quality of life
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma…
- Trial name
- NCT07015242
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 40 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Brain Cancer, Glioblastoma
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
- Conditions
- Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis
- Trial name
- NCT06058988
- Testing
- Trastuzumab deruxtecan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR Gene Mutation
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
- Trial name
- NCT03046992
- Testing
- YH25448
- Where
- 16 sites in South Korea
- Volunteers
- 224 people
- Sponsor
- Yuhan Corporation
Parkinson Disease
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers
Study to assess the safety and tolerability of three doses of PBF-509 (80 mg, 160 mg and 240 mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
- Trial name
- NCT02111330
- Testing
- PBF-509
- Where
- 2 sites in Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Neuroendocrine Tumors, Meningioma
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03273712
- Testing
- 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Brain Tumor, Surgery
Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients?
Perioperative pain management for craniotomy patients may be challenging because the commonly used agents such as opioids, gabapentin, and dexmedetomidine also cause sedation, which can confound the neurological exam and can lead…
- Trial name
- NCT05049707
- Testing
- IV magnesium sulfate
- Volunteers
- 110 people
- Sponsor
- Thomas Jefferson University
Metastatic Malignant Neoplasm in the Brain
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases).
- Trial name
- NCT05438212
- Testing
- Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 216 sites in United States, Canada and 1 more
- Volunteers
- 237 people
- Sponsor
- NRG Oncology
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00626730
- Testing
- adjuvant therapy, radiation therapy
- Where
- Switzerland
- Volunteers
- 78 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Spinal Cord Neoplasm
Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia
This study investigates the pre-clinical nano-based analgesics in cells from human dorsal root ganglia (clusters of neurons). Collecting these neurons may help future research related to safe and effective pain treatment.
- Trial name
- NCT04533919
- Testing
- Biospecimen Collection
- Sponsor
- M.D. Anderson Cancer Center
Short Time Examination, Brain Metastases
Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.
Various treatment options are available for brain metastases, depending on factors such as lesion site or number lesions. Radiotherapy is a commonly used treatment.
- Conditions
- Short Time Examination, Brain Metastases, Radiation Necrosis
- Trial name
- DYNFDGTEP (NCT07632092)
- Testing
- CT scan
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acromegaly, GEP-NET
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning…
- Trial name
- OXTEND-01 (NCT05364944)
- Testing
- Debio 4126, Sandostatin LAR, Somatuline ATG
- Where
- 14 sites in Denmark, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Debiopharm International SA
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresectable meningiomas and malignant…
- Trial name
- NCT00002965
- Testing
- Recombinant Interferon Alfa (INF alpha)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
- Trial name
- NCT02014844
- Testing
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.